Exelixis downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded Exelixis to Market Perform from Outperform with a price target of $40, up from $36. The "main driver of our thesis has played out positively," as a judge ruled in the MSN II litigation case for cabozantinib patents, ruling that Exelixis' '349 patent is not invalid but that MSN's ANDA is not infringing, notes the analyst, who now sees limited upside to the story in 2025 beyond zanzalintinib's readout in colorectal cancer. The firm has raised its target on zanzalintinib's probability of success in CRC, which it now pegs at 50%, but views the success of the trial as "a toss-up" given the history of cabometyx's combination with Tecentriq in this indication, the analyst added.
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
EXEL or INCY: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors?
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion
The FDA notified EXEL that its sNDA seeking label expansion of cabozantinib will be discussed at an ODAC meeting in March 2025.
Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?
EXEL's shares move north 25% in a month on the back of strong third-quarter results and raised outlook. We are optimistic about the stock as we believe there is room for growth.
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
3 Reasons Growth Investors Will Love Exelixis (EXEL)
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and CSL Limited Sponsored ADR (CSLLY). But which of these two stocks presents investors with the better value opportunity right now?
Looking for Earnings Beat? Buy These 4 Top-Ranked Stocks
Top-ranked stocks Amazon.com (AMZN), Maplebear Inc. (CART), Exelixis (EXEL) and Doximity (DOCS) are likely to beat on the bottom line in their upcoming releases.
What Makes Exelixis (EXEL) a Strong Momentum Stock: Buy Now?
Does Exelixis (EXEL) have what it takes to be a top stock pick for momentum investors? Let's find out.
